Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 76 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Y90 Microsphere Therapy Clear all
Completed Phase 2 Interventional Results available

TheraSphere for the Treatment of Liver Metastases

NCT00511862
View directory record Official record
Conditions
Colorectal Cancer, Carcinoma, Neuroendocrine, Neoplasm Metastasis
Interventions
Yttrium 90 glass microspheres
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 20, 2026, 8:23 AM EDT
Not listed Phase 2 Interventional

Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver

NCT00408551
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
floxuridine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Goshen Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Goshen, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 20, 2026, 8:23 AM EDT
Completed No phase listed Observational

Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

NCT00530010
View directory record Official record
Conditions
Liver Cancer
Interventions
yttrium Y 90 glass microspheres
Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 20, 2026, 8:23 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein

NCT01887717
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TheraSphere®, Sorafenib
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 20, 2026, 8:23 AM EDT
Recruiting Phase 2 Interventional

The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

NCT05422690
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Induction Chemotherapy Triplet Therapy, Concurrent Y-90 treatment, Consolidation Doublet Therapy:
Drug · Radiation
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

NCT03457948
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm
Interventions
Arterial Embolization, Pembrolizumab, Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate, Yttrium-90 Microsphere Radioembolization
Procedure · Biological · Device
Lead sponsor
Nicholas Fidelman, MD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver

NCT01473004
View directory record Official record
Conditions
Stage IV Uveal Melanoma
Interventions
Sir-Spheres®
Device
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

Low-dose Y90 Treatment Planning for HCC

NCT04172714
View directory record Official record
Conditions
HCC, Cancer of Liver, Cancer
Interventions
SIR-Spheres microspheres
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 20, 2026, 8:23 AM EDT
Completed No phase listed Observational

Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres

NCT04903548
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
SIRT with Y-90 resin microspheres
Procedure
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases

NCT02195011
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
SIR-Spheres, Regorafenib
Device · Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
St. Petersburg, Florida • Kansas City, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 20, 2026, 8:23 AM EDT
Active, not recruiting Phase 2 Interventional

TheraSphere With Durvalumab and Tremelimumab for HCC

NCT05063565
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 8:23 AM EDT
Terminated Phase 1 Interventional

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer

NCT04108481
View directory record Official record
Conditions
Colorectal Cancer Metastatic, Colon Cancer, Metastatic Colorectal Cancer, Rectal Cancer, Liver Metastasis Colon Cancer, Colo-rectal Cancer, Colorectal Adenocarcinoma, Colorectal Neoplasms, Liver Metastases, Colorectal Carcinoma
Interventions
Durvalumab, Yttrium-90 RadioEmbolization
Drug · Radiation
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 20, 2026, 8:23 AM EDT
Active, not recruiting No phase listed Observational

Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT

NCT02119065
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Liver Metastases, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
positron emission tomography, computed tomography
Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

NCT02602327
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer, Liver Metastases
Interventions
Tas-102, SIR-Sphere
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 20, 2026, 8:23 AM EDT
Terminated Not applicable Interventional

Internal Radiation Therapy in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery

NCT00469963
View directory record Official record
Conditions
Liver Cancer
Interventions
quality-of-life assessment, yttrium Y 90 resin microspheres
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 20, 2026, 8:23 AM EDT
Active, not recruiting Phase 1 Interventional

SIRT With Tremelimumab and Durvalumab for Resectable HCC

NCT05701488
View directory record Official record
Conditions
Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
Interventions
Durvalumab, Tremelimumab, SIRT
Drug · Device
Lead sponsor
Jiping Wang, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 20, 2026, 8:23 AM EDT
Completed No phase listed Observational

TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)

NCT00683631
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TheraSphere HUD
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 20, 2026, 8:23 AM EDT
Terminated Not applicable Interventional Results available

Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia

NCT03059030
View directory record Official record
Conditions
Thrombocytopenia, Cirrhosis
Interventions
TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 20, 2026, 8:23 AM EDT
Withdrawn Phase 2Phase 3 Interventional

FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma

NCT00735241
View directory record Official record
Conditions
Colorectal Carcinoma, Liver Metastases
Interventions
SIR-Spheres microspheres, FOLFOX6 cycles 1-3, FOLFOX6 cycles 4 onwards, Bevacizumab cycles 3 onwards
Device · Drug
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Royal Oak, Michigan • Charlotte, North Carolina • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated May 22, 2015 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets

NCT01581307
View directory record Official record
Conditions
Liver Cancer, Pancreatic Cancer
Interventions
FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin), TheraSpheres
Drug · Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 20, 2026, 8:23 AM EDT
Completed No phase listed Observational

Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer

NCT00739167
View directory record Official record
Conditions
Liver Cancer, Metastatic Cancer
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 16, 2015 · Synced Oct 20, 2026, 8:23 AM EDT
Active, not recruiting Not applicable Interventional

Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients

NCT04736121
View directory record Official record
Conditions
Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Interventions
Resin microspheres containing yttrium-90 (Y-90)
Device
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
22
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 20, 2026, 8:23 AM EDT
Completed Not applicable Interventional

Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma

NCT01176604
View directory record Official record
Conditions
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
Yttrium Y 90 Glass Microspheres
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 20, 2026, 8:23 AM EDT
Active, not recruiting Not applicable Interventional

Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device

NCT06192758
View directory record Official record
Conditions
Prostate, Cancer
Interventions
TheraSphere PCa
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
50 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 20, 2026, 8:23 AM EDT